<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03496623</url>
  </required_header>
  <id_info>
    <org_study_id>RIN-PH-304</org_study_id>
    <nct_id>NCT03496623</nct_id>
  </id_info>
  <brief_title>A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With PH Due to COPD</brief_title>
  <official_title>A Phase 3, Randomized, Placebo-controlled, Double-blind, Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Patients With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>United Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>United Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, placebo-controlled, 30-week, adaptive
      cross-over study, with a Treatment Period of approximately 26 weeks under the Original Design
      or, if applicable, a 17-week parallel study, with a Treatment Period of approximately 14
      weeks under the Contingent Design.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 27, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6-Minute Walk Distance (6MWD) from Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The intent of the 6-Minute Walk Test (6MWT) is a validated and reliable measure of exercise ability in patients with chronic respiratory diseases.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Borg dyspnea score from Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The Borg dyspnea score is a 10 point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no dyspnea at all) to 10 (very, very severe dyspnea).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life (QOL) measured by St. George's Respiratory Questionnaire (SGRQ) from Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The SGRQ is a designed to measure impact on overall health, daily life, and perceived well-being in patients with obstructive airways disease. Scores range from 0 to 100, with higher scores indicating more limitations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in QOL measured by the University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ) from Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The UCSD SOBQ is a self-administered rating of dyspnea associated with activities of daily living. The questionnaire uses a 6-point scale where 0 = &quot;not at all&quot; and 5 = &quot;maximal or unable to do because of breathlessness&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in plasma concentration of N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) levels from Baseline to Week 12</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>The NT-proBNP concentration is a biomarker associated with changes in right heart morphology and function.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Pulmonary Hypertension</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Inhaled Treprostinil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled treprostinil delivered via an ultrasonic nebulizer with a target dosing regimen of 12 breaths (72 mcg) 4 times daily (QID)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo delivered via an ultrasonic nebulizer for QID administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inhaled treprostinil solution</intervention_name>
    <description>Treprostinil inhalation solution</description>
    <arm_group_label>Inhaled Treprostinil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo solution</intervention_name>
    <description>Placebo solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Participants who meet the following criteria may be included in the study:

          1. Subject voluntarily gives informed consent to participate in the study.

          2. Males and females 18 years of age and above at the time of informed consent.

               1. Women of childbearing potential (defined as less than 1 year post-menopausal and
                  not surgically sterile) must agree to practice abstinence or use 2 highly
                  effective methods of contraception (defined as a method of birth control that
                  results in a low failure rate, [&lt;1% per year], such as approved hormonal
                  contraceptives, barrier methods [such as condom or diaphragm] used with a
                  spermicide, or an intrauterine device) for the duration of study treatment and
                  for 48 hours after discontinuing study drug. Subject must have a negative
                  pregnancy test at the Screening Visit 1 (urine [prior to the first dose of study
                  medication] and serum) and Baseline Visit (Study Week 1) (urine).

               2. Males with a partner of childbearing potential must agree to use a barrier method
                  (condom) with a spermicide for the duration of treatment and for at least 48
                  hours after discontinuing study drug.

          3. Diagnosis of PH-COPD (WHO Group 3).

          4. Clinical diagnosis of COPD will be made using the Global Initiative for Chronic

             Obstructive Lung Disease (GOLD) diagnostic criteria (GOLD Criteria 2019) and
             spirometry with the following documented parameters measured during Screening Visit 1
             (prior to start of low-dose inhaled treprostinil):

               1. Forced expiratory volume in 1 second (FEV1) &lt;80% predicted

               2. FEV1/Forced vital capacity (FVC) &lt;70

          5. The subject has a resting saturation peripheral capillary oxygenation (SpO2) greater
             than or equal to 90%, with or without supplemental oxygen, but not to exceed 10 L/min
             oxygen supplementation by any mode of delivery at rest during Screening Visit 1.

          6. During Screening Visit 1 prior to start of low-dose inhaled treprostinil, a 6MWD
             greater than or equal to 100 meters.

          7. Have a right heart catheterization (RHC) performed during Screening Visit 1. (A
             previous RHC obtained within 12 months prior to the start of Screening Visit 1 is
             acceptable for determining eligibility, even if done without oxygen or vasodilator
             challenge, and a repeat RHC is not required.) The following parameters must be
             documented for eligibility:

               1. PVR greater than or equal to 4 Wood units

               2. A pulmonary artery wedge pressure (PAWP) or left ventricular end-diastolic
                  pressure (LVEDP) of less than or equal to 15 mmHg

               3. A PAPm of greater than or equal to 30 mmHg

          8. Participants must be on a stable and optimized dose of chronic COPD medications for
             greater than or equal to 60 days prior to start of Screening Visit 1 and remain on the
             same dose throughout the Screening Period.

          9. Participants on medications for conditions unrelated to COPD must be on a stable and
             optimized dose for greater than or equal to 30 days prior to start of Screening Visit
             1 and should remain on the same dose until the end of the study. Exceptions are
             anticoagulants and diuretics.

         10. In the opinion of the Investigator, the subject can communicate effectively with study
             personnel and is considered reliable, willing, and likely to be cooperative with
             protocol requirements, including attending all study visits.

        Exclusion Criteria:

        The following will exclude participants from the study:

          1. The subject has a diagnosis of either pulmonary arterial hypertension (PAH) or
             pulmonary hypertension (PH) due to reasons other than COPD. This would include, but is
             not limited to, chronic thromboembolic PH or acute/recent deep vein thrombosis or
             pulmonary embolism, untreated or inadequately treated obstructive sleep apnea,
             connective tissue disease (including but not limited to systemic sclerosis/scleroderma
             or systemic lupus erythematosus), sarcoidosis, human immunodeficiency virus-1
             infection, and other conditions under WHO Group 1, 2, 4, and 5 classifications.

          2. Based on chest CT imaging during Screening Visit 1, the subject has a confirmed
             diagnosis of WHO Group 3 PH, other than COPD, such as idiopathic pulmonary fibrosis,
             combined pulmonary fibrosis and emphysema, diffuse parenchymal lung disease or
             interstitial lung disease. A previous chest CT scan performed within the 6 months
             prior to the start of Screening Visit 1 is also acceptable, and a repeat assessment is
             not required.

             A redacted CT scan report (from Screening Visit 1 or dated within prior 6 months)
             should be provided to the Medical Monitor with the Pre-Baseline Review Form to confirm
             eligibility.

          3. The subject has received any Food and Drug Administration (FDA)-approved medication
             for the treatment of PAH (ie, prostacyclin, prostacyclin receptor agonist, endothelin
             receptor antagonist [ERA], phosphodiesterase type 5 inhibitor [PDE5-I], or soluble
             guanylate cyclase [sGC] stimulator) within 60 days of start of Screening Visit 1,
             except if received for acute vasoreactivity testing.

          4. The subject has previously been diagnosed with alpha-1 antitrypsin deficiency.

          5. The subject has had any prior intolerance to prostanoid therapy.

          6. Inability to tolerate low-dose (3 breaths, 18 mcg) study drug and/or inability to
             follow dosing regimen during the Screening Period (pre-randomization).

          7. The subject has evidence of clinically significant left-sided heart disease (including
             but not limited to left ventricular ejection fraction &lt;40%, left ventricular
             hypertrophy,) or clinically significant cardiologic conditions, such as congestive
             heart failure, coronary artery disease, or valvular heart disease. Note: Participants
             with abnormal left ventricular function attributable to the effects of right
             ventricular overload will not be excluded, but a discussion with and approval by the
             Sponsor Medical Monitor is needed.

          8. The subject is receiving &gt;10 L/min of oxygen supplementation by any mode of delivery
             at rest.

          9. Currently using any inhaled tobacco products, electronic cigarettes, or inhaled
             substances, excluding prescribed respiratory therapies, unless approved by the Medical
             Monitor.

         10. Significant history of substance abuse within 6 months prior to start of Screening
             Visit 1.

         11. Any exacerbation of COPD (including hospitalization or outpatient therapy) or active
             pulmonary or upper respiratory infection 60 days prior to start of Screening Visit 1
             through the Baseline Visit. This is defined as worsening of respiratory symptoms that
             required treatment with corticosteroids and/or antibiotics. For the purpose of this
             protocol, treatment of sequalae of COPD are considered COPD exacerbation.

         12. Initiation of pulmonary rehabilitation within 12 weeks prior to start of Screening
             Visit 1 or, in the opinion of the Investigator, pulmonary rehabilitation is likely to
             be needed during the study Treatment Period.

         13. The subject has an uncontrolled medical condition deemed by an Investigator to pose an
             undue risk to the subject.

         14. The subject has any form of congenital heart disease (repaired or unrepaired; other
             than a patent foramen ovale).

         15. The subject has a Body Mass Index greater than or equal to 45 kg/m2 during Screening
             Visit 1.

         16. The subject has any musculoskeletal disorder (ie, arthritis of the lower limbs which
             limits ambulation, recent hip or knee joint replacement, artificial leg) or has any
             other condition that would likely be the primary limitation to ambulation.

         17. Use of any investigational drug/device or participation in any investigational study
             with therapeutic intent within 30 days prior to start of Screening Visit 1.

         18. Any other clinically significant illness or abnormal laboratory value(s) (measured
             during the Screening Period) that, in the opinion of the Investigator, might adversely
             affect the interpretation of the study data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Prakash Sista, Ph.D.</last_name>
    <phone>240-821-1661</phone>
    <email>304perfectstudy@lungbiotechnology.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mary Lou Tomson, M.A.</last_name>
    <phone>240-821-1881</phone>
    <email>304perfectstudy@lungbiotechnology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Weber</last_name>
      <phone>205-975-9964</phone>
      <email>dlowe@uabmc.edu</email>
    </contact>
    <investigator>
      <last_name>Robert Bourge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner University Medical Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phillip Esther</last_name>
      <phone>602-521-3189</phone>
      <email>phillipesther@email.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Raed Alalawi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Arizona Clinical and Translational Science (CATS) Research Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Franz Rischard</last_name>
      <phone>520-626-6308</phone>
      <email>frischard@deptofmed.arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Franz Rischard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Paresh Giri</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Nudell</last_name>
      <phone>323-409-7593</phone>
      <email>Laura.Salguero@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Sivagini Ganesh, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Los Angeles VA Healthcare Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harold Te</last_name>
      <phone>310-268-4314</phone>
      <email>harold.te@va.gov</email>
    </contact>
    <investigator>
      <last_name>Shelley Shapiro, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Macey Sockolov</last_name>
      <email>mlsockolov@ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Roblee Allen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Santa Barbara Pulmonary Associates</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinh Truong</last_name>
      <email>vinht@sblung.com</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Sager, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheri Abbott</last_name>
      <phone>303-724-7466</phone>
      <email>cheryl.abbott@ucdenver.edu</email>
    </contact>
    <investigator>
      <last_name>Todd Bull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sue Derbyshire</last_name>
      <phone>303-703-2124</phone>
      <email>sderbyshire@southdenver.com</email>
    </contact>
    <investigator>
      <last_name>Ira Dauber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Washington Hospital Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Ahmed</last_name>
      <phone>202-877-9328</phone>
      <email>sara.ahmed@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Christopher Barnett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Francis Medical Institute</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ann Gove</last_name>
      <phone>727-210-4606</phone>
      <email>agove@stfrancismed.com</email>
    </contact>
    <investigator>
      <last_name>Francis Averill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Florida Clinical Research Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Eagan</last_name>
      <phone>352-273-8990</phone>
      <email>Christina.Eagan@mediine.ufl.edu</email>
    </contact>
    <investigator>
      <last_name>Hassan Alnuaimat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent's Lung, Sleep, and Critical Care Specialists</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minal Patel</last_name>
      <phone>904-450-8255</phone>
      <email>Minal.Patel@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Jose Soto Soto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inna Abrea</last_name>
      <email>Abrea.Inna@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Charles Burger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary Disease Specialists</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Goodwin</last_name>
      <phone>407-624-4831</phone>
      <email>cgoodwin@pds-cfsc.com</email>
    </contact>
    <investigator>
      <last_name>Thomas O'Brien, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emilia Faraj</last_name>
      <phone>305-243-9383</phone>
      <email>enf16@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>David De La Zerda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Pulmonary &amp; Critical Care of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Wakhisi</last_name>
      <email>Tamara.Wakhisi@northside.com</email>
    </contact>
    <investigator>
      <last_name>Paul Boyce, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Clinical Research</name>
      <address>
        <city>Austell</city>
        <state>Georgia</state>
        <zip>30106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacy Beasley</last_name>
      <phone>770-745-1404</phone>
      <phone_ext>4</phone_ext>
      <email>stacy.beasley@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Amy Case, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Aurora Health Care</name>
      <address>
        <city>Elmhurst</city>
        <state>Illinois</state>
        <zip>60126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Heidenreich</last_name>
      <phone>630-352-2337</phone>
      <email>Debra.heidenreich@advocatehealth.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Ali Valika</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Condell Medical Center</name>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <zip>60048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katharine Szubski</last_name>
      <phone>847-990-2492</phone>
      <email>Katharine.Szubski@advocatehealth.com</email>
    </contact>
    <investigator>
      <last_name>Robert Johnson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Advocate Heart Institute &amp; Pulmonology</name>
      <address>
        <city>Normal</city>
        <state>Illinois</state>
        <zip>06176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alan Ginzburg</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Edward Heart Hospital</name>
      <address>
        <city>Oakbrook Terrace</city>
        <state>Illinois</state>
        <zip>60181</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Molly Wright</last_name>
      <email>mary.wright@advocatehealth.com</email>
    </contact>
    <investigator>
      <last_name>Dr. Maria Rosa Costanzo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Healh North Hospital</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Astin</last_name>
      <email>mastin@iuhealth.org</email>
    </contact>
    <investigator>
      <last_name>William Harvey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Vincent Medical Group, Inc.</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46260</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Slama</last_name>
      <phone>317-338-6717</phone>
      <email>Diane.Slama@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Ashwin Ravichandran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kentuckiana Pulmonary Associates</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martha Royse</last_name>
      <phone>502-587-8000</phone>
    </contact>
    <investigator>
      <last_name>John McConnell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Louisville Research Foundation</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Hamlyn</last_name>
      <phone>502-852-8739</phone>
      <email>Joan.hamlyn@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Karim El-Kersh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lioubov Poliakova</last_name>
      <phone>410-328-6885</phone>
      <email>lpoliako@medicine.umaryland.edu</email>
    </contact>
    <investigator>
      <last_name>Gautam Ramani, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Anne Pulido</last_name>
      <email>npulido@mgh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Josanna Rodriguez-Lopez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariana Faria Urbina</last_name>
      <email>mfariaurbina@bwh.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Elizabeth Gay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Health</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48085</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Samuel Allen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Albany Medical College</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Indrawattie Sukhu</last_name>
      <phone>518-262-9340</phone>
      <email>sukhui1@amc.edu</email>
    </contact>
    <investigator>
      <last_name>Boris Medarov, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Tinuoye</last_name>
      <phone>212-241-7403</phone>
      <email>Elizabeth.Tinuoye@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Sean Pinney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Allison Light</last_name>
      <email>allison_light@urmc.rochester.edu</email>
    </contact>
    <investigator>
      <last_name>Daniel Lachant, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27517</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Blondell Glover</last_name>
      <phone>984-974-2966</phone>
      <email>bpglover@live.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Barbara LeVarge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karla Kennedy</last_name>
      <phone>919-668-1770</phone>
      <email>karla.kennedy@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Terry Fortin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Carl and Edyth Lindner Research Center at the Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deborah Garza</last_name>
      <phone>513-585-1777</phone>
      <email>deborah.garza@thechristhopsital.com</email>
    </contact>
    <investigator>
      <last_name>Peter Engel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Beukemann</last_name>
      <phone>216-444-2140</phone>
      <email>beukemm@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Parambil, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Temple Lung Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gayle Jones</last_name>
      <phone>215-707-1041</phone>
      <email>gayle.jones@tuhs.temple.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Stewart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Spirk</last_name>
      <phone>412-359-4760</phone>
      <email>Tracy.Spirk@ahn.org</email>
    </contact>
    <investigator>
      <last_name>Amresh Raina</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center - Montefiore</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Oriss</last_name>
      <phone>412-692-2210</phone>
      <email>orissca@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Risbano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meghan Ahearn</last_name>
      <phone>401-444-9097</phone>
      <email>megan.ahearn@lifespan.org</email>
    </contact>
    <investigator>
      <last_name>James Klinger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rahul Argula</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Statcare Pulmonary Consultants</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Kesterson</last_name>
      <email>grace.kesterson@biomed-research.com</email>
    </contact>
    <investigator>
      <last_name>John W. Swisher, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daisy Gonzalez</last_name>
      <phone>214-645-1372</phone>
      <email>diasy.gonzalez@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Sonja Bartolome, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Tech</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brenda Castillo</last_name>
      <email>Brenda.Castillo@ttuhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Hernando Garcia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christopher King</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carilion Clinic</name>
      <address>
        <city>Roanoke</city>
        <state>Virginia</state>
        <zip>24014</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Mays</last_name>
      <phone>540-224-6751</phone>
      <email>jlmays@carilionclinic.org</email>
    </contact>
    <investigator>
      <last_name>Sameh Aziz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin School of Medicine and Public Health</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Wollet</last_name>
      <phone>608-263-0524</phone>
      <email>ljwollet@medicine.wisc.edu</email>
    </contact>
    <investigator>
      <last_name>James Runo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Wuerl</last_name>
      <phone>414-955-7036</phone>
      <email>awuerl@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Kenneth Presberg, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CardioPulmonary Research Center</name>
      <address>
        <city>Guaynabo</city>
        <zip>00968</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alvaro Aranda</last_name>
      <phone>(787)545-5125</phone>
      <email>alvaroacc@aol.com</email>
    </contact>
    <investigator>
      <last_name>Alvaro Aranda, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>March 29, 2018</study_first_submitted>
  <study_first_submitted_qc>April 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 12, 2018</study_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary Hypertension</keyword>
  <keyword>COPD</keyword>
  <keyword>Inhaled Treprostinil</keyword>
  <keyword>6-Minute Walk Test</keyword>
  <keyword>Tyvaso</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Treprostinil</mesh_term>
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

